Page 122 - Read Online

24. Qi X, Xie M, Brown AF, Bley CJ, Podlevsky JD, Chen JJ. RNA/DNA 44. Quaas A, Oldopp T, Tharun L, Klingenfeld C, Krech T, Sauter G, Grob
hybrid binding affinity determines telomerase template-translocation TJ. Frequency of TERT promoter mutations in primary tumors of the liver.
efficiency. EMBO J 2012;31:150-61. Virchows Arch 2014;465:673-7.
25. Parks JW, Stone MD. Coordinated DNA dynamics during the human 45. Nagao K, Tomimatsu M, Endo H, Hisatomi H, Hikiji K. Telomerase
telomerase catalytic cycle. Nat Commun 2014;5:4146. reverse transcriptase mRNA expression and telomerase activity in
26. Theimer CA, Jády BE, Chim N, Richard P, Breece KE, Kiss T, Feigon hepatocellular carcinoma. J Gastroenterol 1999;34:83-7.
J. Structural and functional characterization of human telomerase RNA 46. Shimojima M, Komine F, Hisatomi H, Shimizu T, Moriyama M, Arakawa
processing and cajal body localization signals. Mol Cell 2007;27:869-81. Y. (2004) Detection of telomerase activity, telomerase RNA component,
27. Cristofari G, Adolf E, Reichenbach P, Sikora K, Terns RM, Terns MP, and telomerase reverse transcriptase in human hepatocellular carcinoma.
Lingner J. Human telomerase RNA accumulation in Cajal bodies Hepatol Res 2004;29:31-8.
facilitates telomerase recruitment to telomeres and telomere elongation. 47. Cevik D, Yildiz G, Ozturk M. Common telomerase reverse transcriptase
Mol Cell 2007;27:882-9. promoter mutations in hepatocellular carcinomas from different
28. Robart AR, Collins K. Investigation of human telomerase holoenzyme geographical locations. World J Gastroenterol 2015;21:311-7.
assembly, activity, and processivity using disease-linked subunit variants. 48. Valenti L, Dongiovanni P, Maggioni M, Motta BM, Rametta R, Milano
J Biol Chem 2010;285:4375-86. M, Fargion S, Reggiani P, Fracanzani AL. Liver transplantation for
29. Podlevsky JD, Bley CJ, Omana RV, Qi X, Chen JJ. The telomerase hepatocellular carcinoma in a patient with a novel telomerase mutation
database. Nucleic Acids Res 2008;36:D339-43. and steatosis. J Hepatol 2013;58:399-401.
30. Alder JK, Cogan JD, Brown AF, Anderson CJ, Lawson WE, Lansdorp 49. Dikmen ZG, Gellert GC, Jackson S, Gryaznov S, Tressler R, Dogan P,
PM, Phillips JA 3rd, Loyd JE, Chen JJ, Armanios M. Ancestral mutation Wright WE, Shay JW. In vivo inhibition of lung cancer by GRN163L: a
in telomerase causes defects in repeat addition processivity and manifests novel human telomerase inhibitor. Cancer Res 2005;65:7866-73.
as familial pulmonary fibrosis. PLoS Genet 2011;7:e1001352. 50. Burchett KM, Yan Y, Ouellette MM. Telomerase inhibitor Imetelstat
31. Armanios M. Telomerase and idiopathic pulmonary fibrosis. Mutat Res (GRN163L) limits the lifespan of human pancreatic cancer cells. PloS One
2012;730:52-8. 2014;9:e85155.
32. Nishio N, Kojima S. Recent progress in dyskeratosis congenita. Int J 51. Molckovsky A, Siu LL. First-in-class, first-in-human phase I results
Hematol 2010;92:419-24. of targeted agents: highlights of the 2008 American society of clinical
33. Vulliamy T, Marrone A, Dokal I, Mason PJ. Association between aplastic oncology meeting. J Hematol Oncol 2008;1:20.
anaemia and mutations in telomerase RNA. Lancet 2002;359:2168-70. 52. Parsch D, Brassat U, Brümmendorf TH, Fellenberg J. Consequences of
34. Hoare M, Das T, Alexander G. Ageing, telomeres, senescence, and liver telomerase inhibition by BIBR1532 on proliferation and chemosensitivity
injury. J Hepatol 2010;53:950-61. of chondrosarcoma cell lines. Cancer Invest 2008;26:590-6.
35. Podlevsky JD, Chen JJ. It all comes together at the ends: telomerase 53. Bryan C, Rice C, Hoffman H, Harkisheimer M, Sweeney M, Skordalakes
structure, function, and biogenesis. Mutat Res 2012;730:3-11. E. Structural basis of telomerase inhibition by the highly specific
36. Carulli L. Telomere shortening as genetic risk factor of liver cirrhosis. BIBR1532. Structure 2015;23:1934-42.
World J Gastroenterol 2015;21:379-83. 54. Kellermann G, Kaiser M, Dingli F, Lahuna O, Naud-Martin D, Mahuteau-
37. Wiemann SU, Satyanarayana A, Tsahuridu M, Tillmann HL, Zender L, Betzer F, Loew D, Ségal-Bendirdjian E, Teulade-Fichou MP, Bombard
Klempnauer J, Flemming P, Franco S, Blasco MA, Manns MP, Rudolph S. Identification of human telomerase assembly inhibitors enabled by a
KL. Hepatocyte telomere shortening and senescence are general markers novel method to produce hTERT. Nucleic Acids Res 2015;43:e99.
of human liver cirrhosis. FASEB J 2002;16:935-42. 55. Chen ZF, Qin QP, Qin JL, Zhou J, Li YL, Li N, Liu YC, Liang H. Water-
38. Kitada T, Seki S, Kawakita N, Kuroki T, Monna T. Telomere shortening in soluble ruthenium(II) complexes with chiral 4-(2,3-dihydroxypropyl)-
chronic liver-diseases. Biochem Biophys Res Commun 1995;211:33-9. formamide oxoaporphine (FOA): in vitro and in vivo anticancer activity
39. Liu B, Zhang JL, Huang C, Liu H. Dyskerin overexpression in human by stabilization of G-quadruplex DNA, inhibition of telomerase activity,
hepatocellular carcinoma is associated with advanced clinical stage and and induction of tumor cell apoptosis. J Med Chem 2015;58:4771-89.
poor patient prognosis. PLoS One 2012;7:e43147. 56. Wei C, Ren L, Gao N. Interactions of terpyridines and their Pt(II)
40. Mizuno H, Honda M, Shirasaki T, Yamashita T, Yamashita T, Mizukoshi E, complexes with G-quadruplex DNAs and telomerase inhibition. Int J
Kaneko S. Heterogeneous nuclear ribonucleoprotein A2/B1 in association Biol Macromol 2013;57:1-8.
with hTERT is a potential biomarker for hepatocellular carcinoma. Liver 57. Staff C, Mozaffari F, Frodin JE, Mellstedt H, Liljefors M. Telomerase
Int 2012;32:1146-55. (GV1001) vaccination together with gemcitabine in advanced pancreatic
41. Lechel A, Holstege H, Begus Y, Schienke A, Kamino K, Lehmann U, cancer patients. Int J Oncol 2014;45:1293-303.
Kubicka S, Schirmacher P, Jonkers J, Rudolph KL. Telomerase deletion 58. Kotsakis A, Papadimitraki E, Vetsika EK, Aggouraki D, Dermitzaki EK,
limits progression of p53-mutant hepatocellular carcinoma with short Hatzidaki D, Kentepozidis N, Mavroudis D, Georgoulias V. A phase II
telomeres in chronic liver disease. Gastroenterology 2007;132:1465-75. trial evaluating the clinical and immunologic response of HLA-A2(+)
42. Farazi PA, Glickman J, Jiang S, Yu A, Rudolph KL, DePinho RA. non-small cell lung cancer patients vaccinated with an hTERT cryptic
Differential impact of telomere dysfunction on initiation and progression peptide. Lung Cancer 2014;86:59-66.
of hepatocellular carcinoma. Cancer Res 2003;63:5021-7. 59. Mizukoshi E, Nakagawa H, Kitahara M, Yamashita T, Arai K,
43. Huang DS, Wang Z, He XJ, Diplas BH, Yang R, Killela PJ, Meng Q, Ye Sunagozaka H, Fushimi K, Kobayashi E, Kishi H, Muraguchi A, Kaneko
ZY, Wang W, Jiang XT, Xu L, He XL, Zhao ZS, Xu WJ, Wang HJ, Ma YY, S. Immunological features of T cells induced by human telomerase
Xia YJ, Li L, Zhang RX, Jin T, Zhao ZK, Xu J, Yu S, Wu F, Liang J, Wang reverse transcriptase-derived peptides in patients with hepatocellular
S, Jiao Y, Yan H, Tao HQ. (2015) Recurrent TERT promoter mutations carcinoma. Cancer Lett 2015;364:98-105.
identified in a large-scale study of multiple tumour types are associated 60. Xi LH, Cech TR. Inventory of telomerase components in human cells
with increased TERT expression and telomerase activation. Eur J Cancer reveals multiple subpopulations of hTR and hTERT. Nucleic Acids Res
2015;51:969-76. 2014;42:8565-77.

Hepatoma Research | Volume 2 | May 6, 2016 113